2.25
-0.12 (-5.06%)
| Previous Close | 2.37 |
| Open | 2.35 |
| Volume | 151,045 |
| Avg. Volume (3M) | 153,656 |
| Market Cap | 11,553,795 |
| Price / Book | 1.47 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -12.30 |
| Total Debt/Equity (MRQ) | 131.68% |
| Current Ratio (MRQ) | 0.550 |
| Operating Cash Flow (TTM) | -17.91 M |
| Levered Free Cash Flow (TTM) | -6.55 M |
| Return on Assets (TTM) | -62.86% |
| Return on Equity (TTM) | -244.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Cel-Sci Corporation | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | 3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 1.20 |
|
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.20% |
| % Held by Institutions | 5.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gwn Securities Inc. | 31 Mar 2025 | 39,702 |
| Thoroughbred Financial Services, Llc | 31 Mar 2025 | 6,488 |
| Plotkin Financial Advisors, Llc | 31 Mar 2025 | 3,067 |
| Chilton Capital Management Llc | 31 Mar 2025 | 2,386 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KERSTEN GEERT R | 2.29 | - | 2,292 | 5,249 |
| PRICHEP PATRICIA B | 2.29 | - | 1,873 | 4,289 |
| TALOR EYAL | 2.29 | - | 1,048 | 2,400 |
| Aggregate Net Quantity | 5,213 | |||
| Aggregate Net Value ($) | 11,938 | |||
| Aggregate Avg. Buy ($) | 2.29 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KERSTEN GEERT R | Officer | 30 Jun 2025 | Acquired (+) | 2,292 | 2.29 | 5,249 |
| PRICHEP PATRICIA B | Officer | 30 Jun 2025 | Acquired (+) | 1,873 | 2.29 | 4,289 |
| TALOR EYAL | Officer | 30 Jun 2025 | Acquired (+) | 1,048 | 2.29 | 2,400 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |